Stock Watch: Merck & Co’s Anti-IRA Litigation Is A Risky Gambit

Fighting Drug Price Renegotiation Risks Reputational Damage And Unintended Consequences

 
• By Andy Smith
  
Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Stock Watch

More from Business